This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
This was a prospective, randomised, blind, single-centre study. Treatment allocations were generated using the random number function of Microsoft Excel Version 7.0 software and were concealed in individual opaque envelopes until shortly before the patient was anaesthetised.
Analysis of effectiveness
The analysis of effectiveness was conducted on an intention to treat basis. The primary outcomes were: the time of anaesthesia, brain condition, the number of hypertensive episodes, the number of hypotensive episodes, the number of patients who received labelotol, the number of patients who received ephedrine, postoperative nausea and vomiting (PONV), and the times to spontaneous respiration, eye opening, extubation and obeying commands.
There were no statistically significant differences between the two groups in terms of their age, gender, height, weight, body max index, operation (tumour/aneurysm/microvascular) and location (supratentorial/posterior fossa). A regression analysis was performed to explore the relationship between recovery time and hypotensive episodes.
Effectiveness results
Anaesthesia time was longer in group P, but the difference was not statistically significant, 200 minutes (range: 107 to 310) versus 164 minutes (range: 90 to 350), (p=0.082).
There were no statistically significant differences in brain condition between the two groups.
Arterial pressure before, during and after surgery was similar in the two groups.
Hypertensive episodes were seen in 7 patients in group P and 8 patients in group S. These patients experienced a median of 1 (range: 1 to 7) and 1 (range: 1 to 4) hypertensive episodes, respectively. The difference was not statistically significant, (p=0.374, chi-squared test).
Labetolol was given to 14 patients in group P (mean total dose 45 mg, standard deviation (SD)=33) and 19 in group S (mean total dose 76 mg, SD=58), (p=0.073).
Hydralazine was given to 2 patients in group P and 5 patients in group S.
Hypotensive episodes were seen in 15 patients (median 2, range: 1 to 4) in group P and 23 patients (median 3, range: 1 to 7) in group S, (p=0.053).
Ephedrine was given to 63% of patients in group P and 88% of group S. The total doses were 4.8 (2.2) mg in group P, and 9.8 (5.6) mg in group S, (p=0.02).
